



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

EXAMINER

ART UNIT	PAPER NUMBER
----------	--------------

33

DATE MAILED:

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

(1) Cara Colburn

(3) David Eoff

(2) Glady Menvey

(4) Robert Dell'Orco

Date of interview 4.17.02

Deborah Reynolds
Michael Wilson

Type: ☐ Telephonic ☒ Personal (copy is given to ☐ applicant ☒ applicant's representative)

Exhibit shown or demonstration conducted: ☒ Yes ☐ No If yes, brief description: Fig of experiment
3 claims x 2.

Agreement ☐ was reached. ☒ was not reached.

Claim(s) discussed: proposed claims

Identification of prior art discussed: Zanetti, Zambidis, Romet-Lemoune

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: out rejection
regarding new proposed claims were discussed.

Arguments regarding function of cells in art in
combination with functional language added to the
proposed claims will be considered. Enablement
issues and objection were discussed.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☒ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign this form unless it is an attachment to another form.

Wm

A complete written statement as to the substance of any face-to-face or telephone interview with regard to an application must be made of record in the application, whether or not an agreement with the examiner was reached at the interview.

§1.133 Interviews

(b) In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for response to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

§ 1.2. Business to be transacted in writing. All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete a two-sheet carbon interleaf Interview Summary Form for each interview held after January 1, 1978 where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks in neat handwritten form using a ball point pen. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below.

The Interview Summary Form shall be given an appropriate paper number, placed in the right hand portion of the file, and listed on the "Contents" list on the file wrapper. The docket and serial/register cards need not be updated to reflect interviews. In a personal interview, the duplicate copy of the Form is removed and given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephonic interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the telephonic interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Serial Number of the application
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (personal or telephonic)
- Name of participant(s) (applicant, attorney or agent, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the claims discussed
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). (Agreements as to allowability are tentative and do not restrict further action by the examiner to the contrary.)
- The signature of the examiner who conducted the interview
- Names of other Patent and Trademark Office personnel present.

The Form also contains a statement reminding the applicant of his responsibility to record the substance of the interview.

It is desirable that the examiner orally remind the applicant of his obligation to record the substance of the interview in each case unless both applicant and examiner agree that the examiner will record same. Where the examiner agrees to record the substance of the interview, or when it is adequately recorded on the Form or in an attachment to the Form, the examiner should check a box at the bottom of the Form informing the applicant that he need not supplement the Form by submitting a separate record of the substance of the interview.

It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview:

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted;
- 2) an identification of the claims discussed,
- 3) an identification of specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner. The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he feels were or might be persuasive to the examiner.
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete or accurate, the examiner will give the applicant one month from the date of the notifying letter or the remainder of any period for response, whichever is longer, to complete the response and thereby avoid abandonment of the application (37 CFR 1.135(c)).

Examiner to Check for Accuracy

Applicant's summary of what took place at the interview should be carefully checked to determine the accuracy of any argument or statement attributed to the examiner during the interview. If there is an inaccuracy and it bears directly on the question of patentability, it should be pointed out in the next Office letter. If the claims are allowable for other reasons of record, the examiner should send a letter setting forth his or her version of the statement attributed to him. If the record is complete and accurate, the examiner should place the indication "Interview record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

BEST AVAILABLE COPY

3. A composition comprising an expression vector, said expression vector comprising a nucleic acid sequence encoding a fusion protein operatively linked to a promoter, said fusion protein comprising: 1) an immunoglobulin heavy chain or light chain; and 2) a polypeptide or portion thereof containing at least one epitope, said polypeptide selected from the group consisting of: (a) a mammalian antigenic polypeptide; (b) an autoantigenic polypeptide ; and (c) an antigenic polypeptide of an allergen comprising at least two epitopes; wherein the expression vector in a composition induces tolerance.

pa-684340



THE RITZ-CARLTON®

FACSIMILE TRANSMISSION FORM

IMPORTANT NOTICE

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY AT THE TELEPHONE NUMBER LISTED BELOW. THANK YOU.

PLEASE DELIVER IMMEDIATELY

TO: Examiner Michael C. WilsonCOMPANY: US PTOFAX NUMBER: (703) 746-85276 DATE: 4/15/02NUMBER OF PAGES: 3 INCLUDING COVER SHEETFROM: Cavaloburn / Gladys Monay HOTEL: Rm 420

TELEPHONE NUMBER: () FAX NUMBER: ()

REMARKS/SUBJECT:



The Hotel is operated by The Ritz-Carlton Hotel Company, L.L.C. pursuant to express written authority of the owner of the Hotel.

PLEASE CALL

EXT.

IMMEDIATELY IF THE TRANSMISSION

Received from < 11 > at 4/15/02 9:56:30 AM [Eastern Daylight Time] E. THANK YOU.

**TOLEROGENIC FUSION PROTEINS OF IMMUNOGLOBULINS AND
METHODS FOR INDUCING AND MAINTAINING TOLERANCE**

By: David W. SCOTT and Elias T. ZAMBIDIS

Client Ref.: ARC 088 DIV 1

Our Ref.: 30807-20001.10

Examiner Michael C. Wilson

DRAFT CLAIMS FOR DISCUSSION PURPOSES ONLY (INTERVIEW

APRIL 17, 2002)

DO NOT ENTER

1. An expression vector for use in a composition useful for inducing tolerance, said expression vector comprising:
a vector DNA sequence encoding a fusion immunoglobulin heavy chain, light chain, or both heavy chain and light chains, said DNA sequence operably linked to functional transcriptional and translational control regions,
said fusion immunoglobulin comprises a polypeptide or portion thereof containing at least one epitope, said polypeptide selected from the group consisting of: (a) a mammalian antigenic polypeptide; (b) an autoantigenic polypeptide; and (c) an antigenic polypeptide of an allergen comprising at least two epitopes, fused to the variable region of said immunoglobulin heavy or light chain,
wherein the expression vector is for use in a composition useful for inducing tolerance.
2. An expression vector in a composition that induces tolerance, said expression vector comprising a nucleic acid sequence encoding a fusion protein operatively linked to a promoter, said fusion protein comprising: 1) an immunoglobulin heavy chain or light chain; and 2) a polypeptide or portion thereof containing at least one epitope, said polypeptide selected from the group consisting of: (a) a mammalian antigenic polypeptide; (b) an autoantigenic polypeptide; and (c) an antigenic polypeptide of an allergen comprising at least two epitopes; wherein the expression vector in a composition induces tolerance.

pa-684340

pa-684340

TO: Examiner
Michael C. Wilson

Re: S/N 09/160,076
Interview today, 11am

Ex Wilson - Enclosed is
a new set of claims
for discussion purposes
only.

Thank you,
Cara Coburn
Gladys Monroy

Pages = 3 (incl. covers)

**TOLEROGENIC FUSION PROTEINS OF IMMUNOGLOBULINS AND
METHODS FOR INDUCING AND MAINTAINING TOLERANCE**

By: David W. SCOTT and Elias T. ZAMBIDIS

Client Ref.: ARC 088 DIV 1

Our Ref.: 30807-20001.10

Examiner Michael C. Wilson

NEW SET OF DRAFT CLAIMS FOR DISCUSSION PURPOSES ONLY
(INTERVIEW APRIL 17, 2002)
DO NOT ENTER

1. A pharmaceutical composition that induces tolerance to an antigen, said tolerogenic composition comprising a lymphoid cell suitable for introduction into an individual and a pharmaceutically acceptable excipient, wherein said cell contains a polynucleotide sequence encoding a fusion immunoglobulin heavy chain, light chain, or both heavy chain and light chains,

said fusion immunoglobulin comprises a polypeptide or portion thereof containing at least one epitope fused to the variable region of said immunoglobulin heavy or light chain;

wherein said lymphoid cell expresses a tolerogenic amount of fusion immunoglobulin.

2. A composition for preparing a tolerogenic composition, said composition comprising:

a lymphoid cell; and

an expression vector, said expression vector comprising a polynucleotide sequence encoding a fusion immunoglobulin heavy chain, light chain, or both heavy chain and light chains,

said fusion immunoglobulin comprises a polypeptide or portion thereof containing at least one epitope fused to the variable region of said immunoglobulin heavy or light chain.

3. A transformed lymphoid cell for preparing a tolerogenic composition, comprising a polynucleotide sequence encoding a fusion immunoglobulin heavy chain, light chain, or both heavy chain and light chains,

said fusion immunoglobulin comprises a polypeptide or portion thereof containing at least one epitope fused to the variable region of said immunoglobulin heavy or light chain,

wherein said lymphoid cell expressed a tolerogenic amount of fusion immunoglobulin.

pa-684340

Received from <202 887 0763> at 4/17/02 10:17:23 AM [Eastern Daylight Time]

Production and presentation of IgG fusion protein in B cells

